RNS Number : 0813V
Kromek Group PLC
16 September 2026

16 September 2026

Kromek Group plc
("Kromek" or the "Company" or the "Group")

Notice of Investor Webinar

Kromek Group plc (AIM: KMK), a global detection company delivering best-in-class solutions for the advanced imaging and CBRN detection markets, announces that Arnab Basu, CEO, and Claire Burgess, CFO, will be hosting an online Q&A session for investors at 4.00pm BST on Monday 21 September 2026 via the Kromek Investor Hub. This follows the release of the Group's final results for the year ended 30 April 2026 on 14 September 2026.

A pre-recorded results presentation will be uploaded to the Kromek Investor Hub on Friday 18 September 2026 and will be accessible here: https://investors.kromek.com/webinars/epJYXP-kromek-final-results-2026-presentation.

Shareholders can register to attend the live Q&A session, or pre-submit questions, via the registration page here: https://investors.kromek.com/webinars/PwblAr-kromek-final-results-2026-live-q-a.

Questions can also be asked live during the Q&A session.

For further information, please contact:

Investor questions on this announcement	
We encourage all investors to share questions on this announcement via our investor hub	https://investors.kromek.com/link/egL2pr
Kromek Group plc	
Arnab Basu, CEO	+44 (0)1740 626 060
Claire Burgess, CFO	
Cavendish Capital Markets Limited (Nominated Adviser and Broker)	
Geoff Nash/Giles Balleny/Seamus Fricker – Corporate Finance	+44 (0)20 7220 0500
Andrew Burdis – ECM	
Michael Johnson – Sales	
Gracechurch Group (Financial PR)	
Harry Chathli/Claire Norbury	+44 (0)20 4582 3500

Engage with the Kromek management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our interactive investor hub here: https://investors.kromek.com/

Subscribe to our news alert service: https://investors.kromek.com/auth/signup

Kromek Group plc

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek

has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAAKABPQBKDPCD